171 related articles for article (PubMed ID: 32992358)
21. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K
Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
[TBL] [Abstract][Full Text] [Related]
22. Serum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant Frombenign Breast Tumors.
Sai Baba KSS; Rehman MA; Pradeep Kumar J; Fatima M; Raju GSN; Uppin SG; Mohammed N
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2509-2507. PubMed ID: 34452565
[TBL] [Abstract][Full Text] [Related]
23. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
24. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
[TBL] [Abstract][Full Text] [Related]
25. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant and post-surgical treatment in non-epithelial ovarian cancer.
El Helali A; Kwok GST; Tse KY
Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():74-85. PubMed ID: 34493450
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
28. Human epididymal protein 4 (HE4) is a novel biomarker and a promising prognostic factor in ovarian cancer patients.
Chudecka-Głaz A; Rzepka-Górska I; Wojciechowska I
Eur J Gynaecol Oncol; 2012; 33(4):382-90. PubMed ID: 23091895
[TBL] [Abstract][Full Text] [Related]
29. The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
Hemmingsen CH; Kjaer SK; Bennetsen AKK; Dehlendorff C; Baandrup L
Gynecol Oncol; 2021 Aug; 162(2):469-474. PubMed ID: 34016454
[TBL] [Abstract][Full Text] [Related]
30. Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC Consortium.
Braicu EI; Van Gorp T; Nassir M; Richter R; Chekerov R; Gasimli K; Timmerman D; Vergote I; Sehouli J
J Ovarian Res; 2014; 7():49. PubMed ID: 24872845
[TBL] [Abstract][Full Text] [Related]
31. Overview of non-epithelial ovarian tumours: Incidence and survival in the Netherlands, 1989-2015.
van der Hel OL; Timmermans M; van Altena AM; Kruitwagen RFPM; Slangen BFM; Sonke GS; van de Vijver KK; van der Aa MA
Eur J Cancer; 2019 Sep; 118():97-104. PubMed ID: 31326731
[TBL] [Abstract][Full Text] [Related]
32. Correlation analysis and clinical significance of CA125, HE4, DDI, and FDP in type II epithelial ovarian cancer.
Qiao L; Chen X; Xi X; Chen X; Zhang P; Dong H; Wu X; Chen X
Medicine (Baltimore); 2020 Dec; 99(49):e23329. PubMed ID: 33285710
[TBL] [Abstract][Full Text] [Related]
33. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.
Blackman A; Mitchell J; Rowswell-Turner R; Singh R; Kim KK; Eklund E; Skates S; Bast RC; Messerlian G; Miller MC; Moore RG
Tumour Biol; 2021; 43(1):355-365. PubMed ID: 34957977
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
Dewan R; Dewan A; Jindal M; Bhardawaj M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
[TBL] [Abstract][Full Text] [Related]
36. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.
Ortiz-Muñoz B; Aznar-Oroval E; García García A; Covisa Peris A; Perez Ballestero P; Sanchez Yepes M; Garcia Lozano T; Illueca Ballester C; García Garcia E
Tumour Biol; 2014 Jul; 35(7):7249-58. PubMed ID: 24771264
[TBL] [Abstract][Full Text] [Related]
37. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
38. The role of preoperative serum cancer antigen 125 in malignant ovarian germ cell tumors.
Kim JH; Park JY; Kim JH; Kim YM; Kim YT; Nam JH
Taiwan J Obstet Gynecol; 2018 Apr; 57(2):236-240. PubMed ID: 29673667
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass.
Gaillard DHK; Lof P; Sistermans EA; Mokveld T; Horlings HM; Mom CH; Reinders MJT; Amant F; van den Broek D; Wessels LFA; Lok CAR; ;
Int J Gynecol Cancer; 2024 May; 34(5):713-721. PubMed ID: 38388177
[TBL] [Abstract][Full Text] [Related]
40. Value of inhibin in the identification of granulosa cell tumors of the ovary.
Hildebrandt RH; Rouse RV; Longacre TA
Hum Pathol; 1997 Dec; 28(12):1387-95. PubMed ID: 9416696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
